Welcome to our dedicated page for Inhibrx Biosciences SEC filings (Ticker: INBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences, Inc. (INBX) reports that director Douglas Forsyth received a grant of 10,000 stock options on June 3, 2026, as corrected in this amended Form 4. The options have an exercise price of $95.22 per share and cover 10,000 shares of common stock.
The options become fully exercisable on June 3, 2027, subject to Mr. Forsyth’s continued service through that date, and expire on June 3, 2036. Following this grant, Mr. Forsyth holds 10,000 options directly. No Rule 10b5-1 trading plan is reported in connection with this grant.
Inhibrx Biosciences, Inc. (INBX) reports that director Kristiina Vuori, MD received a grant of 10,000 stock options on June 3, 2026, each with an exercise price of $95.22 and expiring on June 3, 2036. The option becomes fully exercisable on June 3, 2027, subject to her continued service, and this amended filing corrects the original option amount reported.
Inhibrx Biosciences, Inc. reported that director Kimberly Manhard received a grant of 10,000 stock options on June 3, 2026. The options have an exercise price of $95.22 per share, become fully exercisable on June 3, 2027 subject to continued service, and expire on June 3, 2036. This amended report corrects the number of options originally disclosed and shows Manhard holding 10,000 options after the grant; the filing states the transactions were not made under a Rule 10b5-1 trading plan.
Inhibrx Biosciences, Inc. (INBX) reports that director Jon Faiz Kayyem received a corrected grant of 10,000 stock options on June 3, 2026, at an exercise price of $95.22 per share. These options become fully exercisable on June 3, 2027, and expire on June 3, 2036, with 10,000 options held directly after the grant. The amended Form 4 restates a prior filing to correct the number of options granted, and no Rule 10b5-1 trading plan is reported.
Inhibrx Biosciences, Inc. (INBX) director Jon Faiz Kayyem reported an open-market purchase of 5,000 shares of common stock on September 16, 2026 at $100 per share, made indirectly through The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Following this transaction, that trust holds 429,360 shares. Additional indirect holdings reported include 250,000 shares held by the Jon Faiz Kayyem Revocable Trust, 250,000 shares held by the Paige Gates-Kayyem Revocable Trust, and 69,843 shares held in a custodial account for each of two minor children, for which the reporting person disclaims beneficial ownership in certain cases except to the extent of any indirect pecuniary interest.
Inhibrx Biosciences, Inc. (INBX) reported that director Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust dated June 4, 2012, sold a total of 1,500 shares of common stock in open market or private transactions on September 11, 14, and 15, 2026 at prices between $105.05 and $111.78 per share. The sales were reported as indirect ownership transactions by the trust, for which Ms. Manhard may be deemed to beneficially own the securities as trustee.
Inhibrx Biosciences, Inc. (INBX) is the issuer for a Rule 144 notice filed on behalf of director Kimberly Manhard, covering planned sales of company common stock. The notice lists 500 shares of common stock to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $52,525.00 and 14,717,660 shares outstanding as of September 15, 2026.
The filing also reports that, during the prior three months, the Kimberly Joan Manhard Revocable Trust sold four blocks of 500 common shares each on September 8, 9, 11, and 14, 2026, for aggregate amounts of $57,570.00, $57,897.50, $55,887.50, and $55,130.00, respectively. The notice states that these sales occurred in the trust, of which Kimberly Manhard is a trustee.
Inhibrx Biosciences, Inc. (INBX) discloses that director Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust and using Fidelity Brokerage Services LLC, has filed a notice to sell 500 shares of common stock. The shares were acquired on August 28, 2024 in an open market purchase and are to be sold for cash, with recent prior sales of 500-share blocks reported over the past three months.
Inhibrx Biosciences, Inc. (INBX) has a Rule 144 notice filed on behalf of director Kimberly Manhard, covering a proposed sale of 500 shares of common stock held in the Kimberly Joan Manhard Revocable Trust. The notice reports that Inhibrx had 14,717,660 shares outstanding as of September 11, 2026. The trust also sold 500 shares for $57,570.00 on September 8, 2026 and 500 shares for $57,897.50 on September 9, 2026, indicating recent selling activity by the same trust account.
Inhibrx Biosciences, Inc. (INBX) director Kimberly Manhard reported indirect sales of common stock held by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. The trust sold 500 shares on September 8, 2026 at $115.14 per share and 500 shares on September 9, 2026 at $115.795 per share. Manhard, as trustee, may be deemed to indirectly beneficially own the trust’s shares, and no Rule 10b5-1 trading plan is reported.